ArticleTranslational lung cancer research2026
LUADnet: a deep learning model for prediction of clinical outcomes in lung adenocarcinoma based on gene expression signatures.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer (NSCLC), and immunochemotherapy is widely utilized in its treatment. However, there are several drawbacks, including immune escape, immune-related adverse events (irAEs), a significant economic burden, and unfavorable outcomes. Therefore, it is crucial to identify patients who are likely to respond to non-immunotherapy. This study aimed to identify key transcriptomic features that distinguish responders from non-responders to non-immunotherapy in LUAD and to develop a deep learning model for effective patient stratification. Methods: Differentially expressed gene (DEG) analysis and functional enrichment analysis were performed on the transcript profile of responders and non-responders from The Cancer Genome Atlas (TCGA). LUADnet model was developed using gene expression data, which integrates the global feature extraction module (GFEM), the local feature extraction module (LFEM), and the channel selection module (CSM), followed by the classifier module. Results: We identified 814 upregulated and 492 downregulated DEGs. Functional enrichment analysis revealed that the upregulated DEGs were enriched in pathways related to immune activation, transmembrane transport, and G protein-coupled receptor (GPCR) signaling, while the downregulated DEGs were primarily associated with the cell cycle pathway. The LUADnet demonstrated superior performance compared to state-of-the-art models, achieving an overall F1-score of 0.9193 and an accuracy of 0.9206. Additionally, ablation experiments indicate that the combination of LFEM, GFEM, and CSM enhances overall classification performance. Conclusions: This study explored the tumor microenvironment of responding and non-responding LUAD patients following non-immunotherapy and developed a robust deep learning model to stratify these patients, which will facilitate therapeutic strategies and alleviate economic burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.